Accueil   Diary - News   All news Poxel Presents Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes

Poxel Presents Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes

  • Imeglimin Phase 2b trial in 299 Japanese patients achieved statistically significant results for its primary and secondary endpoints
  • Poxel recently completed the End of Phase 2 Meeting for Imeglimin with Japanese regulators and plans to initiate the Phase 3 program in the fourth quarter of 2017
  • The Japanese diabetes market is fast-growing and anticipated to reach approximately $6B by 2020

 

  • LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative therapies for metabolic disorders, including type 2 diabetes, announced that results from the Imeglimin Phase 2b study in Japan will be presented today in the Novel Approaches to GlucoseLowering Session in Poster 843 from 1:15-2:15 pm in the Poster Hall at the European Association for the Study of Diabetes (EASD) 53 rd Annual Meeting. This scientific meeting is being held from September 11-15 th in the Parque das Nações, at the International Fair of Lisbon in Portugal.

     

 

 Read the press release